Publicaciones científicas

Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer

04-ene-2019 | Revista: European Journal Clinical Pharmacology

Oyaga-Iriarte E (1), Insausti A (2), Sayar O (2), Aldaz A (3)

(1) Pharmamodelling S.L., Pamplona, Spain.
(2) Pharmamodelling S.L., Pamplona, Spain.
(3) Department of Hospital Pharmacy, Clínica Universidad de Navarra, Pío XII 36, Pamplona, Spain.


PURPOSE:

Irinotecan (CPT-11) is a drug used against a wide range of tumor types. The individualized dosing of CPT-11 is essential to ensure optimal pharmacotherapy in cancer patients, given the wide interindividual pharmacokinetic variability of this drug and its active metabolite SN-38. Moreover, the reabsorption from SN-38-G to SN-38, by enterohepatic recirculation, is critical due to its influence in the treatment tolerance. The aim of this research was to build a joint population pharmacokinetic model for CPT-11 and its metabolites (SN-38, and its glucuronide, SN-38-G) that enabled an individualized posology adjustment.

METHODS:

We used data of 53 treatment cycles of FOLFIRINOX scheme corresponding to 20 patients with metastatic colorectal cancer. In order to build the population pharmacokinetic model, we implemented parametric and non-parametric methods using the Pmetrics library package for R. We also built multivariate regression models to predict the area under the curve and the maximum concentration using basal covariates.

RESULTS:

The final model was a multicompartmental model which represented the transformations from CPT-11 to its active metabolite SN-38 and from SN-38 to inactive SN-38-G. Besides, the model also represented the extensive elimination of SN-38-G and the reconversion of the remaining SN-38-G to SN-38 by enterohepatic recirculation. We carried out internal validation with 1000 simulations. The regression models predicted the PK parameters with R squared adjusted up to 0.9499.

CONCLUSION:

CPT-11, SN-38, and SN-38-G can be correctly described by the multicompartmental model presented in this work. As far as we know, it is the first time that a joint model for CPT-11, SN-38, and SN-38-G that includes the process of reconversion from SN-38-G to SN-38 is characterized.

CITA DEL ARTÍCULO  Eur J Clin Pharmacol. 2019 Jan 4. doi: 10.1007/s00228-018-02609-6

Nuestros autores